Madrigal Pharmaceuticals(MDGL) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., May 1, 2025 – Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction- associated steatohepatitis (MASH), today reports first-quarter 2025 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Since Rezdiffra's approval last year, we've e ...